- $694.24m
- $733.01m
- $502.73m
Brief: Starling Oncology Q2 EPS USD -0.08
Brief: Oncology Institute Rebrands As Starling Oncology
Oncology Institute Q1 revenue rises on specialty pharmacy growth, reaffirms 2026 revenue guidance
Brief: Oncology Institute Q1 Gross Profit USD 23.3 Million
Oncology Institute beats Q4 revenue estimates, net loss narrows
Brief: The Oncology Institute Reaffirms 2025 Guidance And Provides Preliminary 2026 Outlook
Brief: The Oncology Institute Announces Leadership Promotions
Brief: The Oncology Institute Announces Addition Of Board Member Mark Stolper
Brief: The Oncology Institute Announces Resignation Of Board Member Gabe Ling
Oncology Institute Q3 revenue jumps, partly on organic growth in Florida, Oregon
Brief: Oncology Institute Q3 Gross Profit USD 18.9 Million
Oncology Institute Inc reports results for the quarter ended June 30 - Earnings Summary
The Oncology Institute's Q2 revenue up 21.5%, beats estimates
Oncology Institute Inc expected to post a loss of 13 cents a share - Earnings Preview
Brief: Oncology Institute Files For Stock Shelf Of Upto $50 Million
Brief: Oncology Institute Q1 Revenue USD 9 Million
Brief: Oncology Institute Q3 Revenue USD 99.9 Million
Brief: The Oncology Institute Announces CFO Transition
Oncology Institute Inc reports results for the quarter ended in June - Earnings Summary